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Renal function and icu
ABSTRACT
Introduction: The mortality of acute renal failure (ARF) is 50-80% in critically ill patients and has not fallen significantly 
despite numerous advances in critical care strategies and renal replacement technologies over several decades. (1) A 
major problem with conducting research into acute renal failure (ARF) is the lack of a consensus definition (2). More than 
30 different definitions of ARF have been used in the literature. This lack of a common reference point created confusion 
and made comparisons difficult. The Acute Dialysis Initiative (ADQI) group of experts developed and published a consensus 
definition of ARF. This definition goes under the acronym of RIFLE. This definition classified the patients with renal 
dysfunction according to the degree of impairment into patient at risk (R), with injury (I), with failure (F), with sustained loss 
(L) and with end stage (E) status in relation to their renal function. (2) Rifle criteria were based on changes in the patients’ 
glomerular filtration rate (GFR) and/or their urine output. (2)
Discussion: The prophylactic and therapeutic use of dopamine, the more studied vasoactive drug, actually has not been 
supported. For all other vasoactive drugs, at this moment, data available are contradictory and few conclusions can 
be made. To protect renal function, despite wide use of vasoactive drugs, only the maintenance of adequate volume 
replacement and perfusion pressure may be certainly recommended. 
Conclusion: The use of vasoactive drugs is a pervasive practice in intensive care units, and hence, this area needs suitably 
powered, multi-center, randomized, placebo-controlled, double-blind studies to provide more rational indications for 
clinical practice.
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Introduction
The mortality of acute renal failure (ARF) 
is 50-80% in critically ill patients and has 
not fallen significantly despite numerous 
advances in critical care strategies and 
renal replacement technologies over 
several decades. (1)
Postoperative ARF is the most common 
form of ARF in hospitalized patients 
and markedly increases perioperative 
morbidity and mortality. (1) 
The incidence of perioperative ARF 
varies with the type of surgery. Elective 
surgery has a lower risk compared to 
emergency surgery. (1)
Multiple risk factors, including old age, 
chronic renal insufficiency, cardiac di-
sease, sepsis, and concurrent use of 
nephrotoxic agents, such as radiocontrast 
dye and non-steroidal anti-inflammatory 
agents, influence the incidence of ARF in 
intensive care unit  (ICU) patients. (1)
A major problem with conducting 
research into acute renal failure (ARF) 
is the lack of a consensus definition (3). 
Until recently, more than 30 different 
definitions of ARF had been used in 
the literature. This lack of a common 
reference point created confusion 
and made comparisons difficult. The 
Acute Dialysis Initiative (ADQI) group 
of experts developed and published 
a consensus definition of ARF. This 
definition goes under the acronym 
of RIFLE. This definition classified 
the patients with renal dysfunction 
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according to the degree of impairment 
into patient at risk (R), with injury (I), 
with failure (F), with sustained loss (L) 
and with end stage (E) status in relation 
to their renal function. (B) Rifle criteria 
were based on changes in the patients’ 
glomerular filtration rate (GFR) and/or 
their urine output. (2)
Preventive strategies may be considered 
the best strategy to prevent renal 
impairment and consequent renal failure. 
Preventive strategies comprehend 
volume loading to correct hypovolemia, 
use of inotropes and vasopressor agents 
to optimize cardiac output and systemic 
blood pressure, use of renal vasodilators 
to augment renal blood flow and use of 
diuretics to decrease medullary oxygen 
consumption. (1)
Low cardiac output is a risk factor for post-
operative ARF, therefore, perioperative 
cardioprotection plays an important role 
in ARF preventive strategies. (4)
Volume loading is probably the most 
efficient preventive measure to avoid pre-
renal azotemia as well as acute tubular 
necrosis. Monitoring with a central 
venous catheter and, if necessary, with 
a pulmonary artery catheter and/or 
volumetric monitoring as well as PiCCo 
system may guide the amount of fluid to 
be administered to optimize volemia and 
maintain an adequate cardiac output. (1)
It remains unresolved whether colloids 
or crystalloids are the preferred fluid 
for maintaining adequate volume in 
critically ill patients. Low-molecular-
weight hetastarch appears to be safe 
in avoiding hypovolemia in patients with 
capillary leak due to severe inflammation 
and sepsis. (4,5) 
In septic shock and cirrhosis, despite 
markedly diminished systemic vascular 
resistance and hypotension, renal 
vasoconstriction occurs and is well 
documented to be a cause of impaired 
renal perfusion and glomerular filtration 
which represents the hepato-renal 
syndrome. (1) 
In  hepato-renal syndrome, ARF occurs 
in cirrhotic patients with normal kidneys 
but who, importantly, have renal vaso-
constriction, which critically impairs 
renal perfusion and glomerular filtration. 
Renal vasoconstriction is also thought 
to play a role in the pathogenesis of 
septic ARF, along with hypovolemia 
and septic venodilation. (1)
In patients with cardiogenic or vasodilatory 
shock, maintenance of adequate mean 
arterial pressure and cardiac output is 
fundamental for achieving adequate 
vital organ perfusion and function. (6) 
This treatment of hypotension or shock 
comprehends administration of fluid and 
vasoconstrictor drugs that may amplify 
renal ischemia and tubular injury. (6)
Apart from fluid resuscitation, vaso-
active drugs, such as dopamine, 
norepinephrine and epinephrine, are 
often administered in shocked patients 
to improve either cardiac output or 
mean arterial pressure and to achieve 
optimization of organ perfusion and, 
therefore, renal perfusion. (7)
With the exception of dopamine, there 
have been no randomized controlled 
trials of sufficient statistical power to 
detect differences in clinical outcome 
and degree of renal protection. (1)
In critically ill patients, a continuous 
infusion of fenoldopam does not cause 
any clinically significant hemodynamic 
impairment and seems to be a new option 
in improving renal function, compared 
with renal dose dopamine. In early 
acute renal dysfunction, before severe 
renal failure has occurred, the attempt 
to reverse renal hypo-perfusion with 
fenoldopam is more effective than with 
low-dose dopamine.(8) Fenoldopam 
seems to play a role in preventing the 
progression to established acute renal 
failure or accelerating the recovery of 
renal function in critically ill patients.(8)
Landoni et al, in a recent study, suggest 
that fenoldopam reduces mortality and 
the need for renal replacement therapy 
in patients with acute renal injury. (9) 
It is still unclear what hemodynamic 
manipulation is appropriate to obtain 
renal protection and ameliorate renal 
perfusion. (7) Most intensive care unit 
patients receive continuous infusion of 
two or more vasoactive drugs at the 
same time. In intensive care unit patients, 
the main goal is to maintain organ 
perfusion by firstly, attempting a fluid 
challenge and secondly, administering 
drugs. The most commonly used 
drugs in ICU are vasoconstrictors and 
/or vasodilators including different 
inotropic drugs such as norepinephrine, 
epinephrine, dobutamine, levosimendan 
and dopamine.
Actually, the question is whether non-
pharmacological strategies are more 
effective than drugs in preventing acute 
renal failure or progression of renal 
damage? (10)
Cardiovascular drugs
and the kidney in icu
In clinical practice, after an adequate 
preload index has been achieved with 
volume loading, a loop diuretic is 
started to increase urine output. Although 
most clinical studies report an effective 
increase in urine output, the evidence 
for a beneficial effect of loop diuretics 
on renal function is limited. It is probable 
that the patients who responding to loop 
diuretics are characterized by a less 
severe form of renal failure. (11) Other 
clinical studies show a deleterious effect 
of loop diuretics on renal function. (11) 
None of these studies have statistical 
power. An explanation may be an 
excessive pre-load reduction with renal 
vasoconstriction due to activation of 
the renin-angiotensin system and 
sympathetic stimulation, on the other 
hand, loop diuretics induced diuresis 
relies only on decreased reabsorption 
in non-obstructed tubuli, whereas 
tubular obstruction is not prevented or 
remedied. (11) Also the final effect of 
loop diuretics on renal blood flow is the 
resultant of several partially opposing 
effects and the net effect is difficult to 
predict.(11) 
In the same manner mannitol has also 
been used for renal protection. The 
osmotic diuresis may induce volume 
depletion and increased distal solute 
delivery may increase medullary 
oxygen consumption. Mannitol has 
been shown to induce apoptosis in 
endothelial and epithelial cells, and high 
doses can induce acute renal failure 
too. (11) For this reason mannitol has 
not been proven to be a value for renal 
protection. (11)
Dopamine was the first drug used in 
ICUs. The first clinical description of 
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its use was in patients with congestive 
heart failure (12). Dopamine acts on two 
populations of dopamine receptors, 
DA1 and DA2, located on cells in 
vascular smooth muscle of the renal, 
mesenteric, coronary, cerebral, gastric 
and hepatic arteries. The binding of 
dopamine to these receptors results 
in localized arterial vasodilatation, 
increase in glomerular filtration rate, 
renal blood flow and sodium excretion. 
(13) At this dose there is evidence of 
beta1-adrenoreceptor recruitment, 
manifested as increased cardiac output 
and heart rate. (13) 
At higher doses dopamine stimulates 
dopaminergic and adrenergic receptors, 
such as β receptors (3-5 microgram/
Kg/min) and α receptors (above 5 
microgram/Kg/min), with inotropic and 
vasoconstrictor action. (14)
The use of low dose dopamine (1-3 
mcg/kg/min) was widely accepted in 
common clinical practice in an attempt 
to prevent or to treat renal dysfunction. 
A systematic review of 58 studies 
concludes that there is no evidence, 
despite its widespread use, to support 
the use of low dose dopamine to prevent 
or to treat ARF. (14)
The improvement in urine output, of non- 
shocked patients, is only an expression 
of the diuretic effect of dopamine 
rather than its protective effect on renal 
function.(15) Furthermore, this diuretic 
effect wanes by 48 hours after the start 
of a continuous infusion.(16) Despite 
this, in oliguric patients dopamine failed 
to reverse oliguria or hypotension, and 
did not significantly modify clearance 
of creatinine, incidence of acute renal 
failure, need for dialysis or patient 
survival.(17)
Particularly in critical patients, dopamine 
has some potential disadvantages, like 
an earlier onset of gut ischemia, tissue 
necrosis and digital gangrene. A meta-
analysis by Kellum et al. excluded any 
effect of dopamine on the risk of ARF or 
mortality, although dopamine was totally 
inefficient in preventing or treating renal 
dysfunction.(14) The only dopamine 
effect that has been confirmed is the 
temporarily increase in glomerular 
filtration rate in septic shock patients 
due to a reverse in vasoconstriction 
action of vasopressor drugs used in 
these patients (18). The natriuretic effect 
of dopamine increases solute delivery 
to the distal tubular cells, which may 
increase medullar oxygen consumption 
and exacerbate the ischemia during 
hypotension. This effect could explain 
why increases in renal blood flow are 
not protective. (7)
 The ANZIC study analyzed the use of 
dopamine in 324 critically ill patients 
with systemic inflammatory response 
syndrome and oliguria, and confirmed 
that there are no differences in mortality, 
ARF, requirement of renal replacement 
therapy, length of hospital stay or peak 
serum creatinine. (18)
Renal dose dopamine may increase the 
risk of postoperative atrial fibrillation, 
especially in critically ill patients, where 
impaired renal clearance of dopamine 
results in high plasma levels that 
stimulate postsynaptic dopaminergic-
2 receptors. (19) A dopamine infusion 
results in a rapid ventricular response 
and hemodynamic instability due to 
an increase in the atrio-ventricular 
conduction rate.(20) “Low dose” dopa-
mine can worsen renal perfusion in 
patients with acute renal failure, which 
adds to the rationale for abandoning 
the routine use of “low-dose” dopamine 
in critically ill patients.(21)
Although norepinephrine is a very 
common drug used in septic shock 
patients, norepinephrine has only a 
moderate β1 and β2-adrenergic effect 
but a strong α-adrenergic effect, that 
causes vasoconstriction in all vascular 
beds.  The postsynaptic alpha1 receptor 
activity sustains arterial blood pressure 
and peripheral vascular resistance 
but inducing vasoconstriction can 
compromise renal, splanchnic and 
mesenteric blood flow. Dopamine may 
counteract the norepinephrine-induced 
decrease in renal blood flow in healthy 
volunteers.(13)  Actually there are 
insufficient data to define the effect on 
the kidney, either in normal subjects or 
under septic conditions.(7)
The restoration of adequate blood 
pressure using norepinephrine is 
associated with increased urine output, 
but this is achieved with any other drug 
that also improves blood pressure, and 
probably also renal blood flow and 
glomerular filtration rate.(7)
There are no reasons to avoid nore-
pinephrine administration because of 
concerns that it would have a specific 
adverse effect on renal function. When 
compared to high dose dopamine, 
norepinephrine is more effective in res-
toring mean arterial pressure. For this 
reason it is the vasopressor of choice 
in vasodilated hypotensive states with 
preserved or increase cardiac output. (7)
Norepinephrine was more effective in 
restoring normotension in 32 patients 
with hyperkinetic and hypotensive septic 
shock to high dose dopamine.(22)
There are no controlled data to define 
the effects of norepinephrine on the 
kidney in the clinical contest. However, 
many patients’ series have not been 
published. Clinical experience in sep-
tic patients and cardiac patients with 
inflammatory or pharmacological vaso-
dilatation is also positive. At this time, 
there is no reason to fear the effects of 
norepinephrine. If it is used to support 
a vasodilated patient, after adequate 
intravascular filling has occurred and 
after a normal or increased cardiac 
output has been established, it is likely 
to be a friend and not a foe. (23)
In ICU patients some other drugs are 
use less frequently to maintain adequate 
mean arterial pressure.
Phenylephrine, a predominant α1 
adrenergic receptor-mediated agonist, 
increases blood pressure mainly by 
increasing systemic vascular resistance. 
In septic patients it appears not to 
have an adverse effect on the kidney 
and shows a stable serum creatinine 
concentration and increase in urine 
output. (7)
The same effects are noted in post-
operative patients with cardiopulmonary 
bypass. (7)
Recently, vasopressin has been proposed 
as an alternative to catecholamine for 
persistent hypotension in septic shock. 
In catecholamine hypo-responsive 
patients, peripheral vessels respond 
surprisingly well to intravenous injections 
of vasopressin. (24) 
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In healthy patients, vasopressin has 
minimal effect on vascular tone, despite 
successfully restoring blood pressure 
in vasodilating conditions, like septic 
shock or hepato-renal syndrome.(24) 
Vasopressin acts via three types of 
receptors: V1a receptor, located on 
vascular smooth muscle cells, mediates 
vasoconstriction, V2 receptor, mainly 
located on the distal convoluted tubules 
and medullary collecting ducts of the 
kidney, mediates water movements, and 
V3 receptor, mainly located in the anterior 
hypophysis, is involved in the control 
of corticotrophin release. In addition, 
vasopressin is capable of closing acti-
vated ATP-sensitive potassium channels. 
(23) In a septic model, organ blood flow 
through the left ventricle, right ventricle, 
ventricular septum, kidney, liver, spleen 
and skeletal muscle was measured 
using radioisotope tagged micro spheres 
in two groups of patients treated with 
vasopressin or norepinephrine. Vaso-
pressin increased renal blood flow and 
decreased hepatic arterial blood flow, 
whereas, norepinephrine did not. (25)
A multicentric, open-label randomized 
trial in early hyperdynamic septic shock 
found that high-doses of vasopressin, 
used as a single vasopressor agent, 
initially failed to maintain the mean 
arterial pressure above 70 mmHg which 
was the first topic of this trial.(26)
Terlipressin is the drug of choice in 
hepato-renal syndrome: it reverses 
hepato-renal syndrome in 50% of patients, 
and appears safe and well tolerated. (27) 
Terlipressin, in a randomized study, was 
compared to norepinephrine looking 
at the effects on creatinine clearance 
and urine flow in septic patients and the 
authors concluded that renal function is 
improved with both drugs. (28) Morelli 
et al. has previously demonstrated 
that terlipressin decreases oxygen 
consumption, although the measure-
ments were not performed independent 
of cardiac output. (29) Since it has been 
speculated that terlipressin might exhibit 
anti-inflammatory effects that decrease 
oxygen demand of the tissues, the 
reduction of oxygen consumption may 
be interpreted as a positive consequence 
of terlipressin action.(30) 
When other drugs fail to raise mean 
arterial pressure, use of epinephrine 
may be necessary. Epinephrine acts 
simultaneously on α- and β-receptors. 
At low doses it has β- adrenergic effects 
and increases cardiac output. At higher 
doses, its α-adrenergic effect causes 
vasoconstriction, particularly in the 
splanchnic and renal vascular bed, and 
results in elevated systemic vascular 
resistances and blood pressure. (31) 
One of the most important uses of 
epinephrine in the ICU is in septic shock 
and besides this,  in cardiopulmonary 
resuscitation.(32)
Epinephrine infusion is associated with 
a significant increase in renal vascular 
resistance and decrease in renal 
blood flow. Absolute RBF index and 
renal oxygen consumption, creatinine 
clearance and urine output remained 
constant. (7)
Epinephrine, despite an increase in 
mean arterial pressure, may cause 
undeliverable splanchnic effects on ICU 
patients such as lower splanchnic flow 
and oxygen uptake, lower mucosal pH 
and higher hepatic vein lactates. (8) 
We have very limited data about the 
renal effects of epinephrine compared 
with placebo or other vasoactive drugs. 
Actually, data available on the renal 
effects of epinephrine are of a level III 
or IV evidence or animal study, and 
knowledge about the renal effects of 
epinephrine is still limited. (7)
In the late phase of septic shock, the 
cause of hypotension is vasodilation 
and cardiac failure with low cardiac 
output. In this phase, the use of inotropic 
drugs in necessary to maintain organ 
perfusion.
Dobutamine is the drug of choice in 
the case of acute heart failure or in 
shock with low cardiac output. (33) In 
ICU patients, the association between 
norepinephrine and dobutamine is most 
frequently seen in septic shock patients 
to maintain mean arterial pressure and 
tissue perfusion.
Dobutamine is a partial agonist towards 
β1- and β2-adrenoceptors with little effect 
on α-adrenoceptors and increases heart 
rate, cardiac index and oxygen delivery 
within a therapeutic range of 1 to 20 mcg/
Kg/min. The inotropic and chronotropic 
actions of dobutamine are associated 
with therapy-derived tachycardia, which 
would bear the potential for increasing 
myocardial oxygen consumption and 
ischemic injury.(34) In normovolemic 
patients, dobutamine increases cardiac 
index with no change or increase in 
systemic blood pressure. In hypovolemic 
patients, the use of dobutamine may 
induce reduction in mean arterial 
pressure (β2 effect) and increase in 
oxygen consumption (35) because of 
potent vasodilatation through activation 
of β adrenergic receptors. (33) 
The specific renal effect is probably due 
to its ability to increase cardiac output. 
The additive effect of cardiac α1 and 
β1 agonist activity gives dobutamine 
a strong cardiac inotropic action., In 
critically ill patients, dobutamine is 
rarely used as a single agent because 
of the vasodilatory β2 effect, and then 
it is difficult to assess the effect of this 
drug alone on the kidney.(7)
The increase in cardiac output and conse-
quential increase in renal blood flow have 
a beneficial effect on renal function, but 
there is insufficient data to recommend 
its use for renal protection. (7)
Dopexamine also increases splanchnic 
and renal perfusion, via a dopaminergic 
effect.(7) Dopexamine  has  marked 
intrinsic agonist activity on β2 adrenergic 
receptors and weak agonist activity on 
DA1 and DA2 dopaminergic and β1 
adrenergic receptors.(36) A total of 351 
articles were analyzed in a systematic 
review of which 3 articles investigated 
the effect of dopexamine on renal 
function in elective high risk surgery and 
1 of these investigated renal perfusion 
in critically ill patients.(37) Despite some 
authors suggesting that dopexamine 
may protect renal function in patients 
undergoing cardiac surgery, there is 
no evidence to suggest a protective 
role in critically ill patients.(37) Some 
protective effects may be attributable to 
a vasodilating action that may unmask 
a covert hypovolemia, necessitating the 
use of additional volume expansion. 
The fluid excess received by the patient 
may explain some beneficial effects 
attributed to dopexamine. (37)
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On the other hand flaws in the study 
methodology further complicate 
interpretation of results and the authors 
conclude that at this moment there is 
insufficient evidence to recommend use 
of dopexamine for protection of either 
hepato, splanchnic or renal perfusion 
in critically ill patients or in high risk 
surgical patients. (37)
In a randomized controlled trial of 102 
critically ill patients, no benefit was 
shown in creatinine clearance in acute 
renal failure requiring renal replacement 
therapy. (38)
A new cardiac inotrope, levosimendan, 
may also have a role in endotoxemic 
ARF. In fact, levosimendan, a myocardial 
calcium sensitizer, may offset sepsis 
induced reduction in myocardial function 
and improve systemic hemodynamics 
as well as augment renal perfusion 
because it blocks ATP-sensitive K+ 
(Katp) channels and mitigates lipopoly-
saccharide-induced inflammatory 
state. (6) 
Levosimendan can protect against 
endotoxemic ARF in the rodent model, 
because of  a reduction of  70% in BUN 
and plasma creatinine concentrations in 
levosimendan treated endotoxemic mice 
compared with placebo-matched.(6) 
Levosimendan protection arose from the 
downstream consequences of lipopoly-
saccharide-mediated inflammatory 
response and a blunting of its secondary 
renal hemodynamic alterations. In fact 
endotoxemic mice develop acute renal 
failure in the absence of avert tubular injury 
or glomerular thromboses. It is reasonable 
to postulate that levosimendan-mediated 
protection arose from reduction in renal 
vascular resistances. This mechanism 
is mediated by reduction of mesangial 
cells contraction and theoretically should 
increase renal glomerular filtrate.(6)
On the other hand, despite recent data 
about the effect of levosimendan on 
kidney, Oldner et al. have shown that 
pre-treatment with levosimendan in 
pigs with septic shock does not affect 
the renal blood flow. (39)
In the case of systemic or pulmonary 
hypertension, some vasodilator drugs 
may be use, like nitroglycerin or sodium 
nitroprusside.
Nitroglycerine is a potent dilator on 
vascular smooth muscle, because it 
inhibits vascular smooth muscle 
contraction by increasing cGMP. (40) 
Nitroglycerine produces venodilation at 
very low dosages, with little additional 
vasodilatation of the venous circulation 
with increasing doses. Nitrates increase 
arterial diameter and improve arterial 
conductance, and at higher doses 
produce dilation of the arteriolar or 
resistance vessels of the body.(41) 
Despite this, renal blood flow remains 
essential ly unchanged or barely 
decrease after  nitroglycerin infusion, 
although reflex sympathetic activity may 
cause secondary vasoconstriction.(41) 
This failure of systemic administration 
of nitroglycerin to increase renal blood 
flow has previously been demonstrated 
in both animals and humans with heart 
failure. These findings indicate a selective 
vasodilatory effect of nitroglycerin on 
renal conductance but not on resistance 
blood vessels.(42) During infusion of 
nitroglycerin in patients with chronic 
heart failure renal sympathetic activity 
decreases in spite of a reduction in 
arterial pressure and cardiac filling 
pressure. This phenomenon is not 
observed in healthy volunteers. (42) 
The attenuation of renal sympathetic 
response contributes to  the beneficial 
effect of nitroglycerin in chronic heart 
failure patients. (42)
Sodium nitroprusside is a peripheral 
vasodilator, acting directly as arterial 
and venous smooth muscle relaxant, 
like nitroglycerin. (43) Its metabolism 
leads to cyanmethemoglobin formation 
and free cyanide ions. From a renal 
point of view it increases renin release 
and contributes to over activity of the 
sympathetic nervous system, that cau-
ses vasoconstriction and reduction in 
renal blood flow.(43)
Many authors are studying the use of 
a new drug, fenoldopam, in preventing 
renal damage in high-risk patients in the 
ICU or during the perioperative period.
Fenoldopam is a selective dopamine 
receptor-I (DA-1) agonist that, at low 
doses (0.06-0.1mcg/Kg/min), causes 
DA-1 receptor mediated vasodilatation, 
preferentially at afferent arterioles and 
then reduces renal vascular resistances 
and improves renal blood flow, fractional 
excretion of sodium and free water 
clearance.(7) Fenoldopam is a six times 
more effective renal vasodilator  than 
dopamine and does not activate  other 
adrenergic receptors. At doses of 0.1 
mcg/Kg/min no significant decrease in 
systolic blood pressure was observed, 
whereas, at higher doses, fenoldopam 
is a potent vasodilator. (43)
In renal transplant patients there seem 
to be no differences in the dopamine 
versus the fenoldopam group, probably 
because these two drugs do not work 
on denervated kidney or the two groups 
are too small to explain statistical 
differences. In fact, the authors report 
a superior trend in urine output, 
serum creatinine and renal vascular 
resistance in the fenoldopam group 
undergoing elective aortic surgery or 
cardiopulmonary bypass.(44) Moreover 
, fenoldopam seems to preserve renal 
function counterbalancing the renal 
vasoconstrictive effects of cyclosporine 
in kidney (45) and liver (46,47) transplant 
patients. 
It is not clear if this promising effect 
would lead to a reduction in morbidity 
and mortality rate and hence, in the cost 
of medical care.(48)
The kidney in icu
For acute renal failure, hemodialysis 
currently offers two options: intermittent 
hemodialysis (IHD), whereby relatively 
short dialysis sessions are performed 
every day or every other day, and 
continuous renal replacement thera-
pies (CRRT), which are performed 
continuously. (49) Recently, slow low 
efficient daily dialysis (SLEDD) was 
introduced as a third possibility. This 
alternative method combines the 
advantages of CRRT with those of IHD. 
CRRT has some theoretical advantages 
to maintain hemodynamic stability that is 
related to the recovery of renal function, 
correction of metabolic acidosis and 
malnutrition, removal of cytokines 
and solute. CRRT also has some 
disadvantages. In fact CRRT needs 
continuous anticoagulation therapy 
and the necessary immobilization for 
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continuous treatment is a potential 
source of problems. (49) 
Continuous renal replacement thera-
pies (CRRT) allow extracorporeal 
treatment in critically ill patients with 
hypercatabolism and fluid overload. 
CRRT have commonly used three types 
of depurative mechanisms: convection, 
diffusion and adsorption by the filtering 
membrane. (50) 
Acute Dialysis Quality Initiative (ADQI) 
in 2002 has defined some criteria to 
start CRRT in clinical practice.
• Anuria - Oliguria (diuresis ≤ 200 ml 
in 12 h)
• Severe metabolic acidosis (pH < 
7.10)
• Hyperazotemia (BUN ≥ 80 mg/100 
ml)
• Hyperkalemia (K+ ≥ 6,5 mEq/L)
• Clinical signs of uremic toxicity
• Severe dysnatremia (Na + ≤ 115 o ≥ 
160 mEq/L)
• Hyperthermia
• Anasarcha or severe fluid overload
• Multiple Organ Failure including renal 
dysfunction
• SIRS, Sepsis or Septic shock with 
renal dysfunction (51)
In septic patients CRRT may remove 
non-selective pro and anti-inflammatory 
mediators. The treatment dose in CRRT 
is a major factor concerning survival in 
acute renal failure in the critically ill patient. 
(50) Despite this, there is accumulating 
evidence of increased efficacy of high-
volume hemofiltration compared to 
conventional continuous veno-venous 
hemofiltration in terms of laboratory and 
clinical improvement, including survival, 
the evidence is still not strong to suggest 
high-volume hemofiltration outside clini-
cal studies. (50) 
Acute renal failure is increasingly seen 
as part of multiple organ dysfunction 
syndrome (MODS) in critically ill patients. 
Severe sepsis and septic shock are 
primary causes of MODS. CRRT may 
remove bacterial lipopolysaccharides 
and other inflammatory mediators. (50) 
Drugs significantly eliminated by 
the kidney are likely to experience 
substantial removal during CRRT, and 
a supplemental dose corresponding 
to the amount of drug removed should 
be administered. (51) In this case, 
it is mandatory to monitor plasma 
concentrations to maintain adequate 
plasma concentrations. (51)
Other blood purification techniques 
using large-pore membranes or plasma 
filtration with adsorbent perfusion are in 
the early stages of clinical testing. (50)
Also in ICU patients, radio-contrast 
nephropathy (RCN) is another cause 
of acute renal failure. The incidence of 
radio-contrast nephropathy is 50% or 
more in high-risk patients, particularly 
those with underlying chronic kidney 
disease, diabetes mellitus or severe 
heart failure. In these patients, prophy-
lactic strategies should be used to 
reduce the risk of renal injury. The 
prevention of renal injury may include 
the limitation of radio-contrast dose, the 
discontinuation of non-selective NSAIDs 
or selective COH-2 for 24-48 hours prior 
to and following the procedure. (48)
Intravenous isotonic saline solutions 
should be administered and in addition 
loop diuretics should be held prior to 
contrast administration. 
The benefit associated with the adminis-
tration of N-acetylcysteine remains 
debatable, but this drug has minimal 
toxicity and is inexpensive. (48)
The use of N-acetylcysteine should 
not, however, provide a false sense 
of protection. Mannitol, dopamine 
and fenoldopam have been shown 
to be ineffective and in some case 
deleterious and should not be used. 
Monitoring renal function following 
the administration of iodinated radio-
contrast is also important in the first 
24-48 hours.
If necessary, renal replacement therapy 
may be used to rapidly remove the 
radio-contrast. 
This is one of the indications for renal 
replacement therapy in the last 20 
years. 
Conclusion
The prophylactic and therapeutic use of 
dopamine, the more studied vasoactive 
drug, has not actually been supported. 
For all other vasoactive drugs, at this 
moment, data available are contra-
dictory and few conclusions can be 
reached. To protect renal function, 
despite wide use of vasoactive drugs, 
only the maintenance of adequate volume 
replacement and perfusion pressure may 
be certainly recommended. 
The use of new interesting vasoactive 
drugs is still a pervasive practice in 
the intensive care unit, but this area 
needs suitably powered, multicentric, 
randomized ,placebo-control led, 
double-blind studies to provide a more 
rational approach to clinical practice or 
to confirm all the preliminary data.
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